PROMETHERA Biosciences S.A./N.V. To Deliver Corporate And Scientific Update Presentations At The SSIEM Annual Symposium 2016
Mont-Saint-Guibert, Belgium, August 31, 2016 – Promethera Biosciences SA, a Belgian biotechnology company with U.S. operations developing a variety of cell therapies for the treatment of inborn liver metabolic diseases (ILMD) and acquired liver diseases with high unmet medical needs, today announces its presence at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2016 from 6-9 September 2016.
The Promethera staff will be available to answer questions throughout the conference at the exhibition, booth no. 35, Palazzo dei Congressi, Piazza John Fitzgerald Kennedy, Rome, Italy. In-booth presentations will be given on Promethera’s current corporate strategy and research and development pipeline on Wednesday September 7 and Thursday September 8 at 12:30-1pm.
The presentations will include an update on the research and development pipeline as well as changes in the strategy and goals for Promethera following the recent acquisition of Cytonet, the international cellular therapy company involving primary human hepatocytes.
This transaction has made Promethera the world’s leading and most advanced cell therapy and regenerative medicine company targeting a broad range of liver diseases. This new strategy and goal set has been designed by the newly expanded executive management team and guided by the Scientific and Medical Advisory Board, appointed in July 2016.
“Many chronic liver diseases continue to present significant unmet medical needs. Now Promethera is the most advanced company in the field of stem cell therapies for the treatment of inborn liver metabolic diseases (ILMD) and acquired liver diseases,” said Dr Joëlle Thonnard, medical director & professor Etienne Sokal, chief innovation & scientific officer at Promethera Biosciences. “It is important for Promethera to share the current advances and experiences on new cell based treatment approaches to these pathologies to the benefit of the entire community. The SSIEM Annual Symposium provides an excellent opportunity to present both the latest corporate and scientific developments of Promethera to the inborn metabolism error medical and scientific community.”
About Promethera Biosciences
Promethera Biosciences is a clinical stage biopharmaceutical company and the global leader in cell therapy and regenerative medicine for the treatment of inborn and acquired liver diseases with no effective therapeutic cure. Promethera uses allogeneic progenitor cells, stem cells and mature hepatocytes that are harvested and purified from non-transplantable, healthy human livers (Heterologous Human Adult Liver-derived Progenitor Cells, HHALPC and Heterologous Human Liver Cells, HHLivC). These technologies have resulted in the development of three different cell products, HepaStem and H2Stem (progenitor/stem cells) and Heparesc® (mature hepatocytes). Promethera specializes in the development of therapeutic options for the treatment of a broad variety of liver diseases. These range from orphan indications, such as rare inborn metabolic diseases including urea cycle disorders (UCD) or inherited diseases such as a1at deficiency (a1-antitrypsin) and hemophilia to large indications such as acute on chronic liver failure (ACLF), fibrosis and nonalcoholic steatohepatits (NASH).
Promethera Biosciences is a spin-off of the Walloon Region-based Université catholique de Louvain (UCL) and was founded in 2009 by Prof. Dr. Etienne Sokal and Sopartec, the tech transfer office (TTO) of UCL. Promethera is headquartered in Mont-Saint-Guibert, Belgium with a U.S. based GMP compliant manufacturing facility in Durham, NC, US. For more information, visit www.promethera.com.
The Promethera staff will be available to answer questions throughout the conference at the exhibition, booth no. 35, Palazzo dei Congressi, Piazza John Fitzgerald Kennedy, Rome, Italy. In-booth presentations will be given on Promethera’s current corporate strategy and research and development pipeline on Wednesday September 7 and Thursday September 8 at 12:30-1pm.
The presentations will include an update on the research and development pipeline as well as changes in the strategy and goals for Promethera following the recent acquisition of Cytonet, the international cellular therapy company involving primary human hepatocytes.
This transaction has made Promethera the world’s leading and most advanced cell therapy and regenerative medicine company targeting a broad range of liver diseases. This new strategy and goal set has been designed by the newly expanded executive management team and guided by the Scientific and Medical Advisory Board, appointed in July 2016.
“Many chronic liver diseases continue to present significant unmet medical needs. Now Promethera is the most advanced company in the field of stem cell therapies for the treatment of inborn liver metabolic diseases (ILMD) and acquired liver diseases,” said Dr Joëlle Thonnard, medical director & professor Etienne Sokal, chief innovation & scientific officer at Promethera Biosciences. “It is important for Promethera to share the current advances and experiences on new cell based treatment approaches to these pathologies to the benefit of the entire community. The SSIEM Annual Symposium provides an excellent opportunity to present both the latest corporate and scientific developments of Promethera to the inborn metabolism error medical and scientific community.”
About Promethera Biosciences
Promethera Biosciences is a clinical stage biopharmaceutical company and the global leader in cell therapy and regenerative medicine for the treatment of inborn and acquired liver diseases with no effective therapeutic cure. Promethera uses allogeneic progenitor cells, stem cells and mature hepatocytes that are harvested and purified from non-transplantable, healthy human livers (Heterologous Human Adult Liver-derived Progenitor Cells, HHALPC and Heterologous Human Liver Cells, HHLivC). These technologies have resulted in the development of three different cell products, HepaStem and H2Stem (progenitor/stem cells) and Heparesc® (mature hepatocytes). Promethera specializes in the development of therapeutic options for the treatment of a broad variety of liver diseases. These range from orphan indications, such as rare inborn metabolic diseases including urea cycle disorders (UCD) or inherited diseases such as a1at deficiency (a1-antitrypsin) and hemophilia to large indications such as acute on chronic liver failure (ACLF), fibrosis and nonalcoholic steatohepatits (NASH).
Promethera Biosciences is a spin-off of the Walloon Region-based Université catholique de Louvain (UCL) and was founded in 2009 by Prof. Dr. Etienne Sokal and Sopartec, the tech transfer office (TTO) of UCL. Promethera is headquartered in Mont-Saint-Guibert, Belgium with a U.S. based GMP compliant manufacturing facility in Durham, NC, US. For more information, visit www.promethera.com.